Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kulveen Sachdeva

Neuromusculoskeletal Medicine & OMM San Ramon, CA Medical Doctor

NPI 1790718138 CMS profile 80580

5401 Norris Canyon Rd Ste 110, San Ramon, CA 94583

Open in the dashboard

General payments

$2,244

157 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kulveen Sachdeva of San Ramon, CA is reported in the CMS Open Payments database as having received $2,244 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $177 5
2024 General $218 5
2023 General $69 3
2022 General $74 4
2021 General $658 47
2020 General $600 51
2019 General $447 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kulveen Sachdeva
  • Neuromusculoskeletal Medicine & OMM median
  • Middle half of Neuromusculoskeletal Medicine & OMM
  • National median

In program year 2025, general payments to Kulveen Sachdeva were reported at $177. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.

Show as a table
Year Kulveen Sachdeva Neuromusculoskeletal Medicine & OMM median Middle half National median
2019 $447 $92 $27–$283 $163
2020 $600 $85 $20–$411 $114
2021 $658 $120 $32–$548 $132
2022 $74 $96 $32–$518 $149
2023 $69 $92 $33–$328 $160
2024 $218 $122 $35–$378 $164
2025 $177 $119 $36–$380 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $736 70 payments
  2. AbbVie, Inc. $455 34 payments
  3. Allergan Inc. $380 32 payments
  4. Eisai Inc. $244 3 payments
  5. Amgen Inc. $125 1 payment
  6. US WorldMeds, LLC $104 4 payments
  7. Lilly USA, LLC $61 4 payments
  8. Amneal Pharmaceuticals LLC $32 2 payments
  9. Sanofi-Aventis U.S. LLC $31 2 payments
  10. Biogen, Inc. $27 2 payments
  11. Other $48 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,117 154 payments
  2. Education $103 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24 1 payment
Products named General payments · program years 2019–2025
  1. AJOVY Central Nervous System $371 31 payments
  2. UBRELVY Neuroscience $368 30 payments
  3. Ajovy Central Nervous System $274 38 payments
  4. UBRELVY Neuroscience $245 22 payments
  5. Leqembi $223 2 payments
  6. BOTOX $160 11 payments
  7. AIMOVIG $125 1 payment
  8. Apokyn $82 3 payments
  9. CREXONT $32 2 payments
  10. AUBAGIO $31 2 payments
  11. Other $251 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

4,546

Median for Neurology: 833

Drug cost

$1,138,868

Median for Neurology: $202,670

Branded share of claims

24.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 17 $240,237
Avonex Pen (4 Pack) Interferon Beta-1a Brand 26 $229,665
Avonex (4 Pack) Interferon Beta-1a Brand 12 $115,092
Plegridy Pen Peginterferon Beta-1a Brand 14 $113,866
Nuplazid Pimavanserin Tartrate Brand 15 $104,498
Aimovig Autoinjector Erenumab-Aooe Brand 64 $56,198
Neupro Rotigotine Brand 29 $30,456
Emgality Pen Galcanezumab-Gnlm Brand 26 $22,896
Ajovy Autoinjector Fremanezumab-Vfrm Brand 27 $21,209
Namzaric Memantine Hcl/Donepezil Hcl Brand 18 $19,003

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$239,633

Of which drugs: $30,901

Medicare patients

816

Average age 77

Services billed

8,064

447 women, 369 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 51%
Ischemic heart disease 24%
Depression 24%
Osteoporosis 23%
Chronic kidney disease 21%
Diabetes 19%
Alzheimer's or dementia 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 13 6,190 $30,901

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $122
$122 — —
Apokyn
  • US WorldMeds, LLC $82
$82 — —
CREXONT
  • Amneal Pharmaceuticals LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine & OMM in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record